AU1455395A - Use of m3 muscarinic antagonists for the treatment of motion sickness - Google Patents

Use of m3 muscarinic antagonists for the treatment of motion sickness

Info

Publication number
AU1455395A
AU1455395A AU14553/95A AU1455395A AU1455395A AU 1455395 A AU1455395 A AU 1455395A AU 14553/95 A AU14553/95 A AU 14553/95A AU 1455395 A AU1455395 A AU 1455395A AU 1455395 A AU1455395 A AU 1455395A
Authority
AU
Australia
Prior art keywords
treatment
motion sickness
muscarinic antagonists
muscarinic
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14553/95A
Other languages
English (en)
Inventor
William Garth Rapeport
Robert Michael Wallis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
PFIZER Ltd
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER Ltd, Pfizer Ltd Great Britain filed Critical PFIZER Ltd
Publication of AU1455395A publication Critical patent/AU1455395A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU14553/95A 1994-01-14 1995-01-04 Use of m3 muscarinic antagonists for the treatment of motion sickness Abandoned AU1455395A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9400600 1994-01-14
GB9400600A GB9400600D0 (en) 1994-01-14 1994-01-14 Treatment of motion seckness
PCT/EP1995/000044 WO1995019164A1 (en) 1994-01-14 1995-01-04 Use of m3 muscarinic antagonists for the treatment of motion sickness

Publications (1)

Publication Number Publication Date
AU1455395A true AU1455395A (en) 1995-08-01

Family

ID=10748758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14553/95A Abandoned AU1455395A (en) 1994-01-14 1995-01-04 Use of m3 muscarinic antagonists for the treatment of motion sickness

Country Status (6)

Country Link
AU (1) AU1455395A (enrdf_load_stackoverflow)
GB (1) GB9400600D0 (enrdf_load_stackoverflow)
IL (1) IL112257A0 (enrdf_load_stackoverflow)
TW (1) TW276995B (enrdf_load_stackoverflow)
WO (1) WO1995019164A1 (enrdf_load_stackoverflow)
ZA (1) ZA95244B (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8816365D0 (en) * 1988-07-08 1988-08-10 Pfizer Ltd Therapeutic agents
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
EP0581767B1 (en) * 1990-05-18 1997-09-03 Merrell Pharmaceuticals Inc. 5H-DIBENZO(a,d)CYCLOHEPTENES AS MUSCARINIC RECEPTOR ANTAGONISTS
GB9121631D0 (en) * 1991-10-11 1991-11-27 Nat Res Dev Pharmaceutical compositions

Also Published As

Publication number Publication date
WO1995019164A1 (en) 1995-07-20
TW276995B (enrdf_load_stackoverflow) 1996-06-01
GB9400600D0 (en) 1994-03-09
IL112257A0 (en) 1995-03-30
ZA95244B (en) 1996-07-15

Similar Documents

Publication Publication Date Title
ZA969520B (en) Use of epinastine for the treatment of pain
AU7545594A (en) Implantable device for the treatment of aedemas
AU7389894A (en) Therapeutic and diagnostic agents for amyloidosis
HUP0600501A3 (en) Use of cs-866 for producing pharmaceutical composition for the treatment of arteriosclerosis
AU4774597A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
AU2806692A (en) Medicament for the treatment of anxiety
GB9414157D0 (en) Medical use
AU4585993A (en) Use of angiotensin ii antagonists for the treatment of hyperlipidaeme
AU1455395A (en) Use of m3 muscarinic antagonists for the treatment of motion sickness
AU4081393A (en) Medicaments for the treatment of anxiety
IL105285A0 (en) Compositions for the treatment of diabetes
IL109981A0 (en) Body care compositions containing colloidal silica and methods for the preparation and use thereof
GB2275191B (en) Use of antifungal compounds in the treatment of skin disorders
GB9420080D0 (en) The treatment of liquids
GB9726223D0 (en) The treatment of materials
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8
HU9502697D0 (en) Drogs for the treatment of retrovirus infections
HU9600725D0 (en) Transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine for the treatment of alzheimer's disease
GB9424471D0 (en) Treatment of emesis
AU6422794A (en) Keep-fit massage toothbrush
HK1027797A (en) Pharmaceutical agents for the treatment of cerebral amyloidosis
AU6988498A (en) Use of norastemizole for the treatment of allergic disorders